Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.

Yukl SA, Shergill AK, McQuaid K, Gianella S, Lampiris H, Hare CB, Pandori M, Sinclair E, Günthard HF, Fischer M, Wong JK, Havlir DV.

AIDS. 2010 Oct 23;24(16):2451-60. doi: 10.1097/QAD.0b013e32833ef7bb.

2.

The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.

Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM, Read S, Kallungal B, Palmer S, Medvik K, Lederman MM, Alatrakchi N, Jacobson JM, Wiegand A, Kearney M, Coffin JM, Mellors JW, Eron JJ; AIDS Clinical Trials Group A5244 team..

PLoS Med. 2010 Aug 10;7(8). pii: e1000321. doi: 10.1371/journal.pmed.1000321.

3.

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel.

Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, Gatell JM, Günthard HF, Hammer SM, Hirsch MS, Jacobsen DM, Reiss P, Richman DD, Volberding PA, Yeni P, Schooley RT; International AIDS Society-USA..

JAMA. 2010 Jul 21;304(3):321-33. doi: 10.1001/jama.2010.1004.

PMID:
20639566
4.

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

Buzón MJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, Gatell JM, Domingo P, Paredes R, Sharkey M, Palmer S, Stevenson M, Clotet B, Blanco J, Martinez-Picado J.

Nat Med. 2010 Apr;16(4):460-5. doi: 10.1038/nm.2111. Epub 2010 Mar 14.

PMID:
20228817
5.

Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.

Archin NM, Cheema M, Parker D, Wiegand A, Bosch RJ, Coffin JM, Eron J, Cohen M, Margolis DM.

PLoS One. 2010 Feb 23;5(2):e9390. doi: 10.1371/journal.pone.0009390.

6.

Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.

McMahon D, Jones J, Wiegand A, Gange SJ, Kearney M, Palmer S, McNulty S, Metcalf JA, Acosta E, Rehm C, Coffin JM, Mellors JW, Maldarelli F.

Clin Infect Dis. 2010 Mar 15;50(6):912-9. doi: 10.1086/650749.

7.

Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects.

Brothers CH, Hernandez JE, Cutrell AG, Curtis L, Ait-Khaled M, Bowlin SJ, Hughes SH, Yeo JM, Lapierre DH.

J Acquir Immune Defic Syndr. 2009 May 1;51(1):20-8. doi: 10.1097/QAI.0b013e31819ff0e6.

PMID:
19282778
8.

The challenge of finding a cure for HIV infection.

Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ.

Science. 2009 Mar 6;323(5919):1304-7. doi: 10.1126/science.1165706. Review.

PMID:
19265012
9.

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.

D:A:D Study Group., Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D'Arminio Monforte A, Friis-Møller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD.

Lancet. 2008 Apr 26;371(9622):1417-26. doi: 10.1016/S0140-6736(08)60423-7. Epub 2008 Apr 2. Erratum in: Lancet. 2008 Jul 26;372(9635):292.

10.

Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.

Gulick RM, Lalama CM, Ribaudo HJ, Shikuma CM, Schackman BR, Schouten J, Squires KE, Koletar SL, Pilcher CD, Reichman RC, Klingman KL, Kuritzkes DR.

AIDS. 2007 Apr 23;21(7):813-23.

PMID:
17415036
11.

Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy.

Persaud D, Ray SC, Kajdas J, Ahonkhai A, Siberry GK, Ferguson K, Ziemniak C, Quinn TC, Casazza JP, Zeichner S, Gange SJ, Watson DC.

AIDS Res Hum Retroviruses. 2007 Mar;23(3):381-90.

PMID:
17411371
12.

ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia.

Maldarelli F, Palmer S, King MS, Wiegand A, Polis MA, Mican J, Kovacs JA, Davey RT, Rock-Kress D, Dewar R, Liu S, Metcalf JA, Rehm C, Brun SC, Hanna GJ, Kempf DJ, Coffin JM, Mellors JW.

PLoS Pathog. 2007 Apr;3(4):e46.

13.

Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy.

Fang CT, Chang YY, Hsu HM, Twu SJ, Chen KT, Lin CC, Huang LY, Chen MY, Hwang JS, Wang JD, Chuang CY.

QJM. 2007 Feb;100(2):97-105.

PMID:
17277317
14.

Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.

Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA 3rd, Acosta EP, Schouten J, Squires KE, Pilcher CD, Murphy RL, Koletar SL, Carlson M, Reichman RC, Bastow B, Klingman KL, Kuritzkes DR; AIDS Clinical Trials Group (ACTG) A5095 Study Team..

JAMA. 2006 Aug 16;296(7):769-81.

PMID:
16905783
15.

Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial.

INITIO Trial International Co-ordinating Committee., Yeni P, Cooper DA, Aboulker JP, Babiker AG, Carey D, Darbyshire JH, Floridia M, Girard PM, Goodall RL, Hooker MH, Mijch A, Meiffredy V, Salzberger B.

Lancet. 2006 Jul 22;368(9532):287-98.

PMID:
16860698
16.

Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells.

Bailey JR, Sedaghat AR, Kieffer T, Brennan T, Lee PK, Wind-Rotolo M, Haggerty CM, Kamireddi AR, Liu Y, Lee J, Persaud D, Gallant JE, Cofrancesco J Jr, Quinn TC, Wilke CO, Ray SC, Siliciano JD, Nettles RE, Siliciano RF.

J Virol. 2006 Jul;80(13):6441-57.

17.

Efficacy of tenofovir as intensification of zidovudine/lamivudine/abacavir fixed-dose combination in the treatment of HIV-positive patients.

Khanlou H, Guyer B, Farthing C.

J Acquir Immune Defic Syndr. 2005 Apr 15;38(5):627-8. No abstract available.

PMID:
15793377
18.

The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution.

Lambotte O, Chaix ML, Gubler B, Nasreddine N, Wallon C, Goujard C, Rouzioux C, Taoufik Y, Delfraissy JF.

AIDS. 2004 May 21;18(8):1147-58.

PMID:
15166530
19.

A long-term latent reservoir for HIV-1: discovery and clinical implications.

Siliciano JD, Siliciano RF.

J Antimicrob Chemother. 2004 Jul;54(1):6-9. Epub 2004 May 26. Review.

PMID:
15163657
20.

Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication.

Ramratnam B, Ribeiro R, He T, Chung C, Simon V, Vanderhoeven J, Hurley A, Zhang L, Perelson AS, Ho DD, Markowitz M.

J Acquir Immune Defic Syndr. 2004 Jan 1;35(1):33-7.

PMID:
14707789

Supplemental Content

Support Center